Consensus Bicycle Therapeutics plc

Stocks

BCYC

US0887861088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:18:40 2026-07-06 EDT			5-day change	1st Jan Change
4.365 ^USD	+0.34%		+4.36%	-38.83%

06-30	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
06-21	Bicycle Therapeutics plc Announces Termination of Janice Bourque from Director Role, Effective June 17, 2026	CI

Evolution of the Average Target: Bicycle Therapeutics plc

Evolution of the Target Price: Bicycle Therapeutics plc

Changes in Analyst Recommendations: Bicycle Therapeutics plc

90745f2f.x-_st4tG_vf51C2TqjBRmZxHSkYSKTjlPkrCBdCH4II.rKGH0eI3v8eyjEHC-3Uyxv0QAHJ_U1aVDASodYP_is6Jn7OF7y-cn5rjYA~48085472261559fadae1652572f3f20d

Analysts' recommendations: Bicycle Therapeutics plc

03-18	Oppenheimer Adjusts Bicycle Therapeutics PT to $36 From $44, Maintains Outperform Rating	MT
03-18	RBC Cuts Price Target on Bicycle Therapeutics to $7 From $11, Keeps Sector Perform, Speculative Risk	MT
25-10-31	RBC Downgrades Bicycle Therapeutics to Sector Perform From Outperform, Cuts Price Target to $11 From $27, Keeps Speculative Risk	MT
25-08-11	Oppenheimer Adjusts Price Target on Bicycle Therapeutics to $44 From $48, Maintains Outperform Rating	MT
25-08-11	RBC Capital Adjusts Price Target on Bicycle Therapeutics to $27 From $25, Maintains Outperform Speculative Risk Rating	MT
25-07-17	RBC Cuts Price Target on Bicycle Therapeutics to $25 From $32, Keeps Outperform, Speculative Risk	MT
25-05-02	RBC Cuts Price Target on Bicycle Therapeutics to $32 From $35, Keeps Outperform, Speculative Risk	MT
24-12-16	B. Riley Adjusts Price Target on Bicycle Therapeutics to $17 From $28, Keeps Neutral Rating	MT
24-11-08	Stephens Starts Bicycle Therapeutics With Equalweight Rating	MT
24-09-06	RBC Initiates Bicycle Therapeutics at Outperform, Speculative Risk With $35 Price Target	MT
24-08-07	B. Riley Downgrades Bicycle Therapeutics to Neutral From Buy, Cuts Price Target to $28 From $33	MT
24-02-21	HC Wainwright Adjusts Bicycle Therapeutics Price Target to $55 From $57, Maintains Buy Rating	MT
23-12-20	JMP Securities Cuts Bicycle Therapeutics Price Target to $32 From $44, Maintains Market Outperform Rating	MT
23-11-03	Morgan Stanley Cuts Price Target on Bicycle Therapeutics to $40 From $42, Maintains Equal-Weight Rating	MT
23-09-12	B. Riley Upgrades Bicycle Therapeutics to Buy From Neutral After Announced Alignment With US FDA on Phase 2/3 Registrational Trial for BT8009 for Metastatic Bladder Cancer; PT is $33	MT
23-08-04	Oppenheimer Adjusts Bicycle Therapeutics Price Target to $48 From $55, Maintains Outperform Rating	MT
23-08-04	JMP Securities Adjusts Price Target on Bicycle Therapeutics to $44 From $46, Maintains Outperform Rating	MT
23-08-04	Needham Adjusts Price Target on Bicycle Therapeutics to $46 From $48, Maintains Buy Rating	MT
23-05-05	Needham Adjusts Price Target on Bicycle Therapeutics to $64 From $67, Maintains Buy Rating	MT
23-03-01	Needham Adjusts Price Target on Bicycle Therapeutics to $67 From $72, Keeps Buy Rating	MT
23-01-05	EF Hutton Initiates Bicycle Therapeutics at Buy, $55 Price Target	MT
22-11-09	JMP Securities Adjusts Price Target on Bicycle Therapeutics to $46 From $70, Maintains Market Outperform Rating	MT
22-09-12	Morgan Stanley Lowers Price Target on Bicycle Therapeutics to $45 From $60, Keeps Equalweight Rating	MT
22-08-31	Cowen Initiates Coverage on Bicycle Therapeutics With Outperform Rating	MT
22-08-22	SVB Securities Lifts Price Target on Bicycle Therapeutics to $50 From $48, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BICYCLE THERAPEUTICS PLC					+190.23%
	ARGENX SE					+6.55%
	WUXI APPTEC CO., LTD.					+18%
	BIONTECH SE					+26.98%
	INSMED INCORPORATED					+76.57%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.46%
	GENMAB A/S					+23.8%
	PHARMAESSENTIA CORPORATION					-26.02%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+9.75%
	EXELIXIS, INC.					-10.36%
	Average					+33.99%
	Weighted average by Cap.					+18.03%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.350USD

Average target price

12.62USD

Spread / Average Target

+190.23%

High Price Target

36.00USD

Spread / Highest target

+727.59%

Low Price Target

5.000USD

Spread / Lowest Target

+14.94%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Oppenheimer
RBC Capital Markets
B. Riley
Stephens Inc.
HC Wainwright
JMP Securities
Morgan Stanley
Needham & Co.
EF Hutton
Cowen
SVB Securities LLC
Barclays
Canaccord Genuity
Piper Sandler
Cantor Fitzgerald
SVB Leerink
Goldman Sachs